Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma. Although the substance has a better effect/side-effect profile, especially with regard to teratogenicity and neurotoxicity, the rate of therapy-induced thrombosis seems comparable to thalidomide. The observed thromboembolic events were accompanied with a high rate of deleterious pulmonary embolism. Interestingly, the substances alone are not thrombogenic but combination with anthracyclines, dexamethasone or erythropesis-stimulating factors increases the risk considerably. As up to one third of patients treated with such combinations are affected, antithrombotic co-medication is highly recommended. This review elucidates the complex interactions between an activated coagulation-system in myeloma patients and the molecular effects of these drugs. This perception is important to choose the proper prophylactic co-medication without increasing the risk of bleeding, especially in first-line treatment, patients with high paraprotein-levels, or thrombopenia, either therapy-induced or due to bone-marrow infiltration.
2
Bellamy WT,
Richter L,
Frutiger Y.
et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
5
Neben K,
Moehler T,
Kraemer A.
et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115: 605-608.
6
Marriott JB,
Clarke IA,
Dredge K.
et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 130: 75-84.
8
Lentzsch S,
Chatterjee M,
Gries M.
et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890.
9
Verhelle D,
Corral LG,
Wong K.
et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
10
Hideshima T,
Chauhan D,
Shima Y.
et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
16
Glasmacher A,
Hahn C,
Hoffmann F,
Naumann R,
Goldschmidt H,
von Lilienfeld-Toal M.
et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-593.
17
Kumar A,
Loughran T,
Alsina M.
et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003; 4: 293-304.
18
Kumar S,
Gertz MA,
Dispenzieri A.
et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34-39.
20
Minnema MC,
Breitkreutz I,
Auwerda JJ.
et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-2046.
21
Zangari M,
Barlogie B,
Anaissie E.
et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
22
Potenza L,
Luppi M,
Morselli M.
et al. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thromb Haemost 2004; 91: 834-836.
24
Cavo M,
Zamagni E,
Cellini C.
et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272-2273.
25
Rajkumar SV.
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/ indolent disease. Semin Hematol 2003; 40 (Suppl. 04) 17-22.
27
Steurer M,
Sudmeier I,
Stauder R.
et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121: 101-103.
28
Rus C,
Bazzan M,
Palumbo A.
et al. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004; 2: 2063-2065.
30
Elice F,
Fink L,
Tricot G.
et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399-405.
31
Bataille R,
Boccadoro M,
Klein B.
et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737.
32
Kyriakou D,
Papadaki H,
Eliopoulos AG.
et al. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int J Hematol 1997; 66: 367-371.
33
Solary E,
Guiguet M,
Zeller V.
et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol 1992; 39: 163-171.
35
Mitchell CA,
Rowell JA,
Hau L.
et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987; 317: 1638-1642.
36
Zivelin A,
Gitel S,
Griffin JH.
et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-901.
39
Corso A,
Lorenzi A,
Terulla V.
et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588-591.
41
Wienhard J,
Bielska B,
Munstedt K.
et al. Increased endothelial thrombomodulin (TM) expression in pregnancies complicated by IUGR. J Perinat Med 2002; 30: 322-328.
44
Ishii H,
Uchiyama H,
Kazama M.
Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623.
48
Ramachandran R,
Klufas AS,
Molino M.
et al. Release of the thrombin receptor (PAR-1) N-terminus from the surface of human platelets activated by thrombin. Thromb Haemost 1997; 78: 1119-1124.
50
Nguyen QD,
De Wever O,
Bruyneel E.
et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 2005; 24: 8240-8251.
51
Schiller H,
Bartscht T,
Arlt A.
et al. Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin- induced cell death in vitro. Int J Clin Pharmacol Ther 2002; 40: 329-335.
52
Gieseler F,
Luhr I,
Kunze T.
et al. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost 2007; 97: 1023-1030.
55
Minnema MC,
Fijnheer R,
De Groot PG.
et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-449.
57
Cleator JH,
Zhu WQ,
Vaughan DE.
et al. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood 2006; 107: 2736-2744.
58
Klarenbach SW,
Chipiuk A,
Nelson RC.
et al. Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res 2003; 92: 272-278.
61
Montalescot G,
Collet JP,
Lison L.
et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-114.
62
Kes P,
Pecanic Z,
Getaldic B.
et al. Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias. Acta Med Croatica 1996; 50: 173-177.
63
Frank RD,
Kunz D,
Wirtz DC.
Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Am J Hematol 2002; 70: 64-71.
65
Mohri H,
Noguchi T,
Kodama F.
et al. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987; 87: 663-668.
66
Bovill EG,
Ershler WB,
Golden EA.
et al. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986; 85: 115-123.
69
Shinagawa A,
Kojima H,
Berndt MC.
et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005; 93: 889-896.
71
DiMinno G,
Coraggio F,
Cerbone AM.
et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77: 157-164.
73
Palumbo A,
Rus C,
Zeldis JB.
et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4: 1842-1845.
74
Zonder JA,
Barlogie B,
Durie BG.
et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403 author reply 404.
75
Hassoun H,
Reich L,
Klimek VM.
et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155-161.
77
Baz R,
Li L,
Kottke-Marchant K.
et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574.
78
Cavo M,
Zamagni E,
Tosi P.
et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
83
Lyman GH,
Khorana AA,
Falanga A.
et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
